TMAO has emerged as a risk factor for Alzheimer’s disease because of its involvement in various pathophysiological pathways, including the aggregation of Aβ peptide and tau protein, which are central to the pathology of Alzheimer’s. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.